Literature DB >> 29477634

Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study.

A Dinh1, H Fessi2, C Duran3, R Batista4, H Michelon5, F Bouchand5, R Lepeule6, D Vittecoq7, L Escaut7, I Sobhani8, C Lawrence9, F Chast4, P Ronco2, B Davido3.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) carriage are increasing worldwide. Faecal microbiota transplantation (FMT) appears to be an attractive option for decolonization. This study aimed to evaluate CRE vs VRE clearance by FMT among carriers.
METHODS: A multi-centre trial was undertaken on patients with CRE or VRE digestive tract colonization who received FMT between January 2015 and April 2017. Adult patients with CRE or VRE colonization, confirmed by three consecutive rectal swabs at weekly intervals, including one in the week prior to FMT, were included in the study. Patients with immunosuppression or concomitant antibiotic prescription at the time of FMT were excluded. Successful decolonization was determined by at least two consecutive negative rectal swabs [polymerase chain reaction (PCR) and culture] on Days 7, 14, 21 and 28, and monthly for three months following FMT.
RESULTS: Seventeen patients were included, with a median age of 73 years [interquartile range (IQR) 64.3-79.0]. Median duration of carriage of CRE or VRE before FMT was 62.5 days (IQR 57.0-77.5). One week after FMT, three of eight patients were free of CRE colonization and three of nine patients were free of VRE colonization. After three months, four of eight patients were free of CRE colonization and seven of eight patients were free of VRE colonization. Qualitative PCR results were concordant with culture. Six patients received antibiotics during follow-up, three in each group. No adverse events were reported.
CONCLUSION: CRE and VRE clearance rates were not significantly different in this study, possibly due to the small sample size, but a trend was observed. These data should be confirmed by larger cohorts and randomized trials.
Copyright © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Carbapenem-resistant Enterobacteriaceae; Carriage; Faecal microbiota transplantation; Vancomycin-resistant enterococci

Mesh:

Year:  2018        PMID: 29477634     DOI: 10.1016/j.jhin.2018.02.018

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  26 in total

1.  Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection.

Authors:  Young Kyung Yoon; Jin Woong Suh; Eun-Ji Kang; Jeong Yeon Kim
Journal:  Ann Med       Date:  2019-09-13       Impact factor: 4.709

2.  Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.

Authors:  Julia L Drewes; Alina Corona; Uriel Sanchez; Yunfan Fan; Suchitra K Hourigan; Melissa Weidner; Sarah D Sidhu; Patricia J Simner; Hao Wang; Winston Timp; Maria Oliva-Hemker; Cynthia L Sears
Journal:  JCI Insight       Date:  2019-10-03

3.  The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections.

Authors:  Yascha Khodamoradi; Johanna Kessel; Jörg Janne Vehreschild; Maria J G T Vehreschild
Journal:  Dtsch Arztebl Int       Date:  2019-10-04       Impact factor: 5.594

4.  Just another crappy commentary: the future of fecal microbiota transplantation.

Authors:  James T Rosenbaum
Journal:  Expert Rev Clin Immunol       Date:  2019-10-08       Impact factor: 4.473

5.  Longitudinal Evaluation of Gut Bacteriomes and Viromes after Fecal Microbiota Transplantation for Eradication of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Qin Liu; Tao Zuo; Wenqi Lu; Yun Kit Yeoh; Qi Su; Zhilu Xu; Whitney Tang; Keli Yang; Fen Zhang; Louis H S Lau; Rashid N S Lui; Miu Ling Chin; Rity Wong; Chun Pan Cheung; Wenyi Zhu; Paul K S Chan; Francis K L Chan; Grace C Lui; Siew C Ng
Journal:  mSystems       Date:  2022-06-01       Impact factor: 7.324

6.  Germs of thrones - spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: is this myth or reality?

Authors:  Benjamin Davido; Aurore Moussiegt; Aurélien Dinh; Frédérique Bouchand; Morgan Matt; Olivia Senard; Laurene Deconinck; Florence Espinasse; Christine Lawrence; Nicolas Fortineau; Azzam Saleh-Mghir; Silvia Caballero; Lelia Escaut; Jérome Salomon
Journal:  Antimicrob Resist Infect Control       Date:  2018-08-13       Impact factor: 4.887

Review 7.  Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives.

Authors:  Livia Gargiullo; Federica Del Chierico; Patrizia D'Argenio; Lorenza Putignani
Journal:  Front Microbiol       Date:  2019-07-25       Impact factor: 5.640

8.  Investigation and Analysis of the Colonization and Prevalence of Carbapenem-Resistant Enterobacteriaceae in Pediatric Liver Transplant Recipients.

Authors:  Yan Sun; Lixin Yu; Wei Gao; Jinzhen Cai; Wentao Jiang; Wei Lu; Yihe Liu; Hong Zheng
Journal:  Infect Drug Resist       Date:  2021-05-25       Impact factor: 4.003

9.  Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae.

Authors:  Juan Carlos Ramos-Ramos; Fernando Lázaro-Perona; José Ramón Arribas; Julio García-Rodríguez; Jesús Mingorance; Guillermo Ruiz-Carrascoso; Alberto M Borobia; José Ramón Paño-Pardo; Rafael Herruzo; Francisco Arnalich
Journal:  Gut Pathog       Date:  2020-04-07       Impact factor: 4.181

10.  Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis.

Authors:  Priyanga Dharmaratne; Nannur Rahman; Anthony Leung; Margaret Ip
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.